Skyrizi
Skyrizi Approved for Crohn’s Disease Treatment
AbbVie announced the FDA’s approval of Skyrizi as the first specific interleukin-23 inhibitor for treatment ...
JUNE 24, 2022

Extended Risankizumab Induction Needed for Some Patients
Some Crohn’s disease patients may require 24 weeks before experiencing a response to treatment with ...
DECEMBER 16, 2021

Load more